Smart Grid

TMCNet:  Research and Markets: ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis 2012-2022

[January 11, 2013]

Research and Markets: ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis 2012-2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/6n6569/asp7374_seasonal) has announced the addition of GlobalData's new report "ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis" to their offering.

ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection.

Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garnr the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Story continues below ↓

ASP7374 (UMN-0502) is a recombinant protein-based vaccine manufactured using a baculovirus expression vector system. UMN Pharma obtained the rights to vaccine development for FluBlok in various Asian countries, including Japan, China, and South Korea, from Protein Sciences Corporation, and subsequently set about to develop UMN-0502 as its own seasonal influenza vaccine. Since the deal, UMN Pharma has licensed the product to Astellas Pharma as part of a development collaboration between the companies.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Appendix

For more information visit http://www.researchandmarkets.com/research/6n6569/asp7374_seasonal

Source (News - Alert): GlobalData


[ Back To Smart Grid Home's Homepage ]




blog comments powered by Disqus